Epizyme Inc. (NASDAQ:EPZM) shares traded down 1.6% on Monday . The stock traded as low as $7.42 and last traded at $7.58, with a volume of 147,232 shares traded. The stock had previously closed at $7.70.

Several research analysts recently weighed in on the stock. Zacks Investment Research cut shares of Epizyme from a “buy” rating to a “hold” rating in a research report on Thursday, May 5th. Wedbush reaffirmed an “outperform” rating and set a $22.00 target price on shares of Epizyme in a report on Monday, May 9th. Mizuho lowered their target price on shares of Epizyme from $20.00 to $18.00 and set a “buy” rating for the company in a report on Tuesday, May 10th. HC Wainwright reaffirmed a “buy” rating on shares of Epizyme in a report on Tuesday, May 10th. Finally, JMP Securities reaffirmed a “buy” rating and set a $28.00 target price on shares of Epizyme in a report on Thursday, June 23rd. One equities research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $23.11.

The stock’s market capitalization is $435.83 million. The stock’s 50-day moving average is $9.37 and its 200 day moving average is $10.36.

Epizyme (NASDAQ:EPZM) last released its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.49) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.52) by $0.03. On average, equities research analysts expect that Epizyme Inc. will post ($2.19) earnings per share for the current fiscal year.

In related news, insider Robert A. Copeland sold 4,000 shares of Epizyme stock in a transaction on Monday, August 1st. The shares were sold at an average price of $10.37, for a total transaction of $41,480.00. Following the completion of the transaction, the insider now owns 35,538 shares of the company’s stock, valued at $368,529.06. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

An institutional investor recently raised its position in Epizyme stock. Jennison Associates LLC boosted its position in Epizyme Inc. (NASDAQ:EPZM) by 252.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 893,913 shares of the biopharmaceutical company’s stock after buying an additional 640,245 shares during the period. Jennison Associates LLC owned 2.14% of Epizyme worth $14,320,000 as of its most recent SEC filing.

Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company’s segment is the discovery and development of novel epigenetic therapies for cancer patients. It develops small molecule inhibitors of a class of enzymes known as histone methyltransferases, or HMTs.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.